Roche buys Santaris

Share this article:
Roche buys Santaris
Roche buys Santaris

Following through with its July assertion that Roche wasn't looking for a mega deal, the Swiss company has gone for a smallish one: the purchase of private biotech Santaris, which is based in Copenhagen.

The $250 million cash deal includes up to an additional $200 million in milestone payments and tucks the Santaris Locked Nucleic Acid drug platform, known as LNA, into Roche's R&D pocket.

It also brings the pharmaceutical industry a bit closer together—Santaris has development agreements with several companies including GlaxoSmithKline, Shire (soon to be known as AbbVie) and Bristol-Myers Squibb.

Roche's research lead John Reed said in a statement that Santaris's platform will help the company develop a new class of medicines, particularly because “there are many disease targets that are very challenging or even impossible to reach with small molecules or antibodies.”

The partners expect to close the deal this month, and Roche said in a statement that it expects to keep the Danish operations open, albeit with the new name Roche Innovation Center Copenhagen.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...